<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a highly aggressive mature B-cell <z:hpo ids='HP_0002664'>neoplasm</z:hpo> consisting of endemic, <z:hpo ids='HP_0003745'>sporadic</z:hpo>, and <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-associated variants, sharing many morphologic and immunophenotypic features </plain></SENT>
<SENT sid="1" pm="."><plain>It is characterized by a high proliferation rate and propensity for extranodal sites such as gastrointestinal tract and reproductive organs </plain></SENT>
<SENT sid="2" pm="."><plain>Brief-duration, high-intensity chemotherapy regimens including aggressive central <z:mp ids='MP_0008912'>nervous</z:mp> system prophylaxis have had remarkable success in the treatment of this disease in the <z:hpo ids='HP_0003745'>sporadic</z:hpo> form, with very high complete remission rate and overall survival in adults </plain></SENT>
<SENT sid="3" pm="."><plain>Although Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is extremely chemosensitive, biologically targeted therapies should be developed, because current treatment options are suboptimal for patients with poor prognostic features or with <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e> </plain></SENT>
</text></document>